Sanifit
Sanifit is a drug development company that is developing treatments for calcification disorders where hydroxyapatite (HAP) crystals form and grow in blood vessels, leading to stiffer and narrower arteries.
Sanifit’s lead compound, SNF472, is a calcification-reducing formulation with the ability for intravenous administration, making SNF472 well-suited and convenient for the treatment of patients with end-stage renal disease (ESRD) suffering from calcification disorders, who must therefore regularly undergo haemodialysis.
